Search results for "Combined"

showing 10 items of 1205 documents

Cytoreductive surgery and mitomycin C hyperthermic intraperitoneal chemotherapy with CO2 recirculation (HIPEC-CO2) for colorectal cancer peritoneal m…

2021

Peritoneal dissemination from colorectal cancer (CRC) has long been associated with unfavorable prognosis. However, in the last decades, the combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was able to obtain up to 30% 5-year survival rate in selected centers. Despite the wide diffusion of CRS and HIPEC, until now, there are no clear recommendations on the drug of choice for HIPEC nor its technique, and safety and efficacy data of HIPEC regimens and techniques are lacking. We performed a retrospective analysis of a prospectively maintained database of 26 CRS and mitomycin C HIPEC with CO2 recirculation (HIPEC-CO2) for CRC peritoneal metastasis…

medicine.medical_specialtyPeritoneal metastasisColorectal cancerMitomycinSettore MED/18 - CHIRURGIA GENERALE2Hyperthermic Intraperitoneal Chemotherapy030230 surgery03 medical and health sciences0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansHyperthermiaAdverse effectSurvival ratePeritoneal NeoplasmsRetrospective StudiesCarcinomatosisHIPECbusiness.industryInducedMitomycin CCommon Terminology Criteria for Adverse EventsCytoreduction Surgical ProceduresHyperthermia InducedCarbon DioxidePrognosismedicine.diseaseColorectal cancerCombined Modality TherapyHIPEC-COSurgerySurvival Rate030220 oncology & carcinogenesisPeritoneal metastasisSurgeryHyperthermic intraperitoneal chemotherapyColorectal NeoplasmsbusinessCytoreductive surgeryUpdates in Surgery
researchProduct

Effects of hormone replacement therapy and high-impact physical exercise on skeletal muscle in post-menopausal women: a randomized placebo-controlled…

2001

An age-related decline in muscle performance is a known risk factor for falling, fracture and disability. In women, a clear deterioration is observed from early menopause. The effect of hormone replacement therapy (HRT) in preserving muscle performance is, however, unclear. This trial examined the effects of a 12-month HRT and high-impact physical exercise regimen on skeletal muscle in women in early menopause. A total of 80 women aged 50–57 years were assigned randomly to one of four groups: exercise (Ex), HRT, exercise+HRT (ExHRT) and control (Co). The exercise groups participated in a high-impact training programme. The administration of HRT (oestradiol/noretisterone acetate) or placebo …

medicine.medical_specialtyPlacebo-controlled studyPhysical exercisePlacebolaw.inventionDouble-Blind MethodRandomized controlled triallawInternal medicineElectric ImpedancemedicineHumansExercise physiologyMuscle SkeletalExerciseAnalysis of VarianceEstradiolbusiness.industryEstrogen Replacement TherapySkeletal muscleGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyBiomechanical PhenomenaPostmenopauseMenopausemedicine.anatomical_structureEndocrinologyTorqueAnesthesiaBody CompositionFemaleNorethindronemedicine.symptomTomography X-Ray ComputedbusinessMuscle contractionClinical Science
researchProduct

Is arthrocentesis of temporomandibular joint with corticosteroids beneficial? A systematic review

2018

Background Temporomandibular disorders (TMDs) are musculoskeletal conditions that can inhibit the normal function of temporomandibular joints (TMJs) and affect the patient’s quality of life, negatively. Arthrocentesis (AC) is a minimally invasive surgical procedure used for treating TMDs. The aim of present paper is to evaluate the advantages of administrating corticosteroid (CS) during AC by reviewing high quality released articles. Material and Methods Searching on Cochrane Library, Web of Science, Google Scholar, PubMed, ProQuest, and Scopus databases were performed with focusing on proper key words. Related titles and abstracts, up to December 2017, were screened and selected based on i…

medicine.medical_specialtyRandomizationmedicine.medical_treatmentMEDLINEPain reliefReviewCochrane Librarylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialQuality of lifestomatognathic systemlawmedicineHumans030212 general & internal medicineGlucocorticoidsGeneral DentistryRandomized Controlled Trials as Topicbusiness.industryArthrocentesis030206 dentistryTemporomandibular Joint Disorders:CIENCIAS MÉDICAS [UNESCO]Combined Modality TherapyTemporomandibular jointstomatognathic diseasesmedicine.anatomical_structureOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASPhysical therapySurgeryOral SurgerybusinessArthrocentesis
researchProduct

Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the…

2022

Abstract Objectives To assess the toxicity patterns and effectiveness of doublet chemotherapy when administered at reduced doses of 20% (FOLFOX or FOLFIRI) in combination with anti-EGFR antibodies (cetuximab or panitumumab) in old, vulnerable patients with metastatic colorectal cancer (mCRC). Patients and methods We performed a retrospective observational study of RAS and BRAF wild-type, vulnerable patients aged ≥70 years with previously untreated mCRC. The primary endpoint was safety, and secondary endpoints were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results One hundred and eighteen patients were collected from 14 selected Italian centres.…

medicine.medical_specialtyReduced doseColorectal cancerLeucovorinCetuximabNeutropeniaGastroenterologyFOLFOXInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansPanitumumabDoublet chemotherapyAnti-EGFRAgedCetuximabMetastatic colorectal cancerRectal Neoplasmsbusiness.industryPanitumumabAnti-EGFRs Doublet chemotherapy Metastatic colorectal cancer Reduced doses Vulnerable older patientsExanthemamedicine.diseaseRashVulnerable older patients.OncologyColonic NeoplasmsFOLFIRIFluorouracilGeriatrics and Gerontologymedicine.symptomColorectal Neoplasmsbusinessmedicine.drugJournal of Geriatric Oncology
researchProduct

Oral propranolol and intravitreal ranibizumab for refractory serous macular detachment secondary to retinal capillary hemangioblastoma

2015

medicine.medical_specialtyRetinal Neoplasmbusiness.industrymedicine.medical_treatmentRetinal detachmentGeneral MedicinePropranololmedicine.diseaseRefractoryOphthalmologyHemangioblastomaMedicineCombined Modality TherapyRanibizumabbusinessLaser coagulationmedicine.drugArchivos de la Sociedad Española de Oftalmología (English Edition)
researchProduct

Retinal vein occlusion: current treatment.

2010

Retinal vein occlusion (RVO) is a pathology noted for more than 150 years. Although a lot has been written on the matter, it is still a frequent condition with multifactorial etiopathogenesis with many unclear aspects. The RVO pathogenesis has varied systemic and local implications that make it difficult to elaborate treatment guidelines. The management of the patient with RVO is very complex and a multidisciplinary approach is required in order to identify and correct the associated risk factors. Laser therapy remains the gold standard in RVO, but only modest functional improvement has been shown in branch retinal occlusion forms. Multicenter studies of intravitreal drugs present them as a…

medicine.medical_specialtyRetinal VeinPegaptanibAngiogenesis Inhibitorschemistry.chemical_compoundCentral retinal vein occlusionOcclusionRetinal Vein OcclusionmedicineHumansIntensive care medicineGlucocorticoidsLaser CoagulationVascular diseasebusiness.industryRetinalGeneral Medicinemedicine.diseaseCombined Modality TherapySensory SystemsSurgeryOphthalmologychemistryIntravitreal InjectionsRanibizumabbusinessRetinopathymedicine.drugOphthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde
researchProduct

Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?

2017

Abstract According to current European guidelines, lipid lowering therapy for progressive cardiovascular disease including cardiovascular events has to be focused on a target level for LDL-C. In contrast for Lp(a) a threshold has to be defined with respect to the method of measurement. However, due to new lipid lowering drug developments like PCSK9-inhibitors (PCSK-9-I) a therapeutic algorithm for patients with severe hypercholesterolemia or isolated Lipoprotein(a)-hyperlipoproteinemia with progressive cardiovascular disease may be necessary to manage the use of PCSK9-I, lipoprotein apheresis (LA) or both. The therapeutic approach for patients with homozygous familial hypercholesterolemia i…

medicine.medical_specialtySerine Proteinase InhibitorsDiseaseFamilial hypercholesterolemia030204 cardiovascular system & hematologyRisk AssessmentHyperlipoproteinemia Type II03 medical and health sciencesTherapeutic approach0302 clinical medicineRisk FactorsInternal medicineGermanyInternal MedicinemedicineHumans030212 general & internal medicinePCSK9 Inhibitorsbiologybusiness.industryPCSK9Anticholesteremic AgentsPCSK9 InhibitorsGeneral MedicineLipoprotein(a)Cholesterol LDLmedicine.diseaseCombined Modality TherapyEndocrinologyTreatment OutcomeCardiovascular Diseasesbiology.proteinCardiologyBlood Component Removallipids (amino acids peptides and proteins)Proprotein Convertase 9Cardiology and Cardiovascular MedicinebusinessLipoprotein apheresisBiomarkersLipoproteinLipoprotein(a)Atherosclerosis. Supplements
researchProduct

Drug Evaluation: The Combination of Fenofibrate and Simvastatin for the Treatment of Dyslipidemia: When and for Whom?

2015

Simvastatin and fenofibrate are the most frequently co-prescribed drugs for the treatment of dyslipidemia, manifesting beneficial effects on non-lipid parameters as well. The combination of these two drugs has been shown to increase success in the management of combined hyperlipidemia. Their different mechanism of action allows for the targeting of two types of lipid abnormalities: increased cholesterol and atherogenic dyslipidemia. Clinical studies have demonstrated that statin and fibrate combination therapy is effective in improving multiple lipid abnormalities, that may further decrease overall cardiovascular (CV) risk of patients with combined dyslipidemia. However, the clinical use of…

medicine.medical_specialtyStatinFenofibrateCombination therapymedicine.drug_classbusiness.industrynutritional and metabolic diseasesFibratemedicine.diseaseClinical trialCombined hyperlipidemiaSimvastatinInternal medicinemedicinelipids (amino acids peptides and proteins)businessDyslipidemiamedicine.drug
researchProduct

Do Running and Strength Exercises Reduce Daily Muscle Inactivity Time?

2016

Understanding how a specific exercise changes daily activity patterns is important when designing physical activity interventions. We examined the effects of strength and interval running exercise sessions on daily activity patterns using recordings of quadriceps and hamstring muscle electromyographic (EMG) activity and inactivity. Five male and five female subjects taking part in a 10-week training programme containing both strength and interval running training sessions were measured for daily muscle EMG activities during three days: on a strength day, an interval running day, and a day without exercise. EMG was measured using textile electrodes embedded into sport shorts that were worn 9…

medicine.medical_specialtyStrength trainingStrength exercisephysical activityfunctional capacityPhysical medicine and rehabilitationmuscle inactivityrunningmedicineMuscle activityta315Training programmeTextile electrodesdaily sedentary timeendurancemuscle activitycombined trainingPhysical activity interventionsbusiness.industrylcsh:Public aspects of medicineTotal measurementlcsh:RA1-1270General Medicinestrength exercisesfitnessPhysical therapybusinessstrengthHamstringResearch ArticleAIMS public health
researchProduct

Can chemotherapy concomitantly delivered with radiotherapy improve survival of patients with resectable rectal cancer? A meta-analysis of literature …

2010

Summary Background There is clear evidence from two systematic reviews that radiotherapy (RT) reduces the risk of local recurrence in patients with resectable rectal cancer, though the data on survival are still equivocal. Objective To assess the effects of chemotherapy combined concomitantly with radiotherapy (CRT) on the increase of overall survival, and on the prevention of local recurrence and distant metastases. Data sources Computerized bibliographic searches of MEDLINE and CANCERLIT (1970–2008) were supplemented with hand searches of reference lists. Study selection Studies were included if they were randomized controlled trials (RCTs) comparing preoperative or postoperative CRT to p…

medicine.medical_specialtySurvivalColorectal cancermedicine.medical_treatmentPopulationAntineoplastic Agentslaw.inventionRectal carcinomaRandomized controlled triallawRisk of mortalityHumansMedicineMeta-analysiRadiology Nuclear Medicine and imagingNeoplasm Metastasiseducationeducation.field_of_studyRadiotherapyRectal Neoplasmsbusiness.industryChemoradiotherapyGeneral Medicinemedicine.diseaseCombined Modality TherapySurgeryRadiation therapyOncologyConcomitantMeta-analysisbusinessPublication BiasChemoradiotherapyCancer Treatment Reviews
researchProduct